209 related articles for article (PubMed ID: 27105284)
1. p97 Composition Changes Caused by Allosteric Inhibition Are Suppressed by an On-Target Mechanism that Increases the Enzyme's ATPase Activity.
Her NG; Toth JI; Ma CT; Wei Y; Motamedchaboki K; Sergienko E; Petroski MD
Cell Chem Biol; 2016 Apr; 23(4):517-28. PubMed ID: 27105284
[TBL] [Abstract][Full Text] [Related]
2. Allosteric p97 Inhibitors Can Overcome Resistance to ATP-Competitive p97 Inhibitors for Potential Anticancer Therapy.
Wang F; Li S; Gan T; Stott GM; Flint A; Chou TF
ChemMedChem; 2020 Apr; 15(8):685-694. PubMed ID: 32162487
[TBL] [Abstract][Full Text] [Related]
3. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death.
Magnaghi P; D'Alessio R; Valsasina B; Avanzi N; Rizzi S; Asa D; Gasparri F; Cozzi L; Cucchi U; Orrenius C; Polucci P; Ballinari D; Perrera C; Leone A; Cervi G; Casale E; Xiao Y; Wong C; Anderson DJ; Galvani A; Donati D; O'Brien T; Jackson PK; Isacchi A
Nat Chem Biol; 2013 Sep; 9(9):548-56. PubMed ID: 23892893
[TBL] [Abstract][Full Text] [Related]
4. Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.
Nishimura N; Radwan MO; Amano M; Endo S; Fujii E; Hayashi H; Ueno S; Ueno N; Tatetsu H; Hata H; Okamoto Y; Otsuka M; Mitsuya H; Matsuoka M; Okuno Y
Cancer Sci; 2019 Oct; 110(10):3275-3287. PubMed ID: 31368616
[TBL] [Abstract][Full Text] [Related]
5. Specific inhibition of p97/VCP ATPase and kinetic analysis demonstrate interaction between D1 and D2 ATPase domains.
Chou TF; Bulfer SL; Weihl CC; Li K; Lis LG; Walters MA; Schoenen FJ; Lin HJ; Deshaies RJ; Arkin MR
J Mol Biol; 2014 Jul; 426(15):2886-99. PubMed ID: 24878061
[TBL] [Abstract][Full Text] [Related]
6. A covalent p97/VCP ATPase inhibitor can overcome resistance to CB-5083 and NMS-873 in colorectal cancer cells.
Zhang G; Li S; Wang F; Jones AC; Goldberg AFG; Lin B; Virgil S; Stoltz BM; Deshaies RJ; Chou TF
Eur J Med Chem; 2021 Mar; 213():113148. PubMed ID: 33476933
[TBL] [Abstract][Full Text] [Related]
7. Small-Molecule Modulators of the ATPase VCP/p97 Affect Specific p97 Cellular Functions.
Figuerola-Conchas A; Saarbach J; Daguer JP; Cieren A; Barluenga S; Winssinger N; Gotta M
ACS Chem Biol; 2020 Jan; 15(1):243-253. PubMed ID: 31790201
[TBL] [Abstract][Full Text] [Related]
8. 2.3 Å resolution cryo-EM structure of human p97 and mechanism of allosteric inhibition.
Banerjee S; Bartesaghi A; Merk A; Rao P; Bulfer SL; Yan Y; Green N; Mroczkowski B; Neitz RJ; Wipf P; Falconieri V; Deshaies RJ; Milne JL; Huryn D; Arkin M; Subramaniam S
Science; 2016 Feb; 351(6275):871-5. PubMed ID: 26822609
[TBL] [Abstract][Full Text] [Related]
9. NMS-873 functions as a dual inhibitor of mitochondrial oxidative phosphorylation.
Bouwer MF; Hamilton KE; Jonker PB; Kuiper SR; Louters LL; Looyenga BD
Biochimie; 2021 Jun; 185():33-42. PubMed ID: 33727138
[TBL] [Abstract][Full Text] [Related]
10. Adapted ATPase domain communication overcomes the cytotoxicity of p97 inhibitors.
Wei Y; Toth JI; Blanco GA; Bobkov AA; Petroski MD
J Biol Chem; 2018 Dec; 293(52):20169-20180. PubMed ID: 30381397
[TBL] [Abstract][Full Text] [Related]
11. A Dynamic molecular basis for malfunction in disease mutants of p97/VCP.
Schuetz AK; Kay LE
Elife; 2016 Nov; 5():. PubMed ID: 27828775
[TBL] [Abstract][Full Text] [Related]
12. The AAA+ ATPase p97, a cellular multitool.
Stach L; Freemont PS
Biochem J; 2017 Aug; 474(17):2953-2976. PubMed ID: 28819009
[TBL] [Abstract][Full Text] [Related]
13. Evaluating p97 Inhibitor Analogues for Potency against p97-p37 and p97-Npl4-Ufd1 Complexes.
Gui L; Zhang X; Li K; Frankowski KJ; Li S; Wong DE; Moen DR; Porubsky PR; Lin HJ; Schoenen FJ; Chou TF
ChemMedChem; 2016 May; 11(9):953-7. PubMed ID: 27043824
[TBL] [Abstract][Full Text] [Related]
14. A unique IBMPFD-related P97/VCP mutation with differential binding pattern and subcellular localization.
Erzurumlu Y; Kose FA; Gozen O; Gozuacik D; Toth EA; Ballar P
Int J Biochem Cell Biol; 2013 Apr; 45(4):773-82. PubMed ID: 23333620
[TBL] [Abstract][Full Text] [Related]
15. Evaluating p97 inhibitor analogues for their domain selectivity and potency against the p97-p47 complex.
Fang CJ; Gui L; Zhang X; Moen DR; Li K; Frankowski KJ; Lin HJ; Schoenen FJ; Chou TF
ChemMedChem; 2015 Jan; 10(1):52-6. PubMed ID: 25377500
[TBL] [Abstract][Full Text] [Related]
16. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways.
Chou TF; Brown SJ; Minond D; Nordin BE; Li K; Jones AC; Chase P; Porubsky PR; Stoltz BM; Schoenen FJ; Patricelli MP; Hodder P; Rosen H; Deshaies RJ
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4834-9. PubMed ID: 21383145
[TBL] [Abstract][Full Text] [Related]
17. VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy.
Lan B; Chai S; Wang P; Wang K
Curr Mol Med; 2017; 17(9):608-618. PubMed ID: 29521227
[TBL] [Abstract][Full Text] [Related]
18. p97 Disease Mutations Modulate Nucleotide-Induced Conformation to Alter Protein-Protein Interactions.
Bulfer SL; Chou TF; Arkin MR
ACS Chem Biol; 2016 Aug; 11(8):2112-6. PubMed ID: 27267671
[TBL] [Abstract][Full Text] [Related]
19. Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis.
Anderson DJ; Le Moigne R; Djakovic S; Kumar B; Rice J; Wong S; Wang J; Yao B; Valle E; Kiss von Soly S; Madriaga A; Soriano F; Menon MK; Wu ZY; Kampmann M; Chen Y; Weissman JS; Aftab BT; Yakes FM; Shawver L; Zhou HJ; Wustrow D; Rolfe M
Cancer Cell; 2015 Nov; 28(5):653-665. PubMed ID: 26555175
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of p97 by chlorinated analogues of dehydrocurvularin.
Tillotson J; Bashyal BP; Kang M; Shi T; De La Cruz F; Gunatilaka AA; Chapman E
Org Biomol Chem; 2016 Jul; 14(25):5918-21. PubMed ID: 27223265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
